Patients with higher anti-Müllerian hormone levels from POSEIDON group 4 benefit from GnRH-agonist long protocol: A retrospective study

Abstract Objective To compare the efficacy of gonadotropin-releasing hormone antagonist versus gonadotropin-releasing hormone agonist long protocol in women belonging to POSEIDON groups 3 and 4. Study design A total of 380 patients with expected low ovarian response [antral follicle count Results In POSEIDON group 4, age, anti-Mullerian hormone, initial gonadotropin dose and induction protocols were significantly correlated with cumulative live birth by multivariate regression analysis. The optimum cut-off value of anti-Mullerian hormone for prediction of cumulative live birth was 0.785 by receiver operating characteristic analysis. Patients with higher anti-Mullerian hormone levels (anti-Mullerian hormone ≥ 0.785 ng/mL) who received the gonadotropin-releasing hormone agonist long protocol achieved significantly higher cumulative live birth rate than who received the gonadotropin-releasing hormone antagonist protocol, whereas no significant difference in cumulative live birth rate of the two protocols was found in patients with low anti-Mullerian hormone levels (anti-Mullerian hormone Conclusions Patients with higher anti-Mullerian hormone levels from POSEIDON group 4 are more likely to benefit from the gonadotropin-releasing hormone agonist long protocol than the gonadotropin-releasing hormone antagonist protocol.